Monistat cream (miconazole nitrate) a new agent for the treatment of vulvovaginal candidiasis.
Monistat Cream (miconazole nitrate 2%), a new fungicidal agent indicated for the treatment of vulvovaginal candidiasis, was evaluated in a comparative study with nystatin vaginal tablets (100,-000 units each). A total of 95 pregnant and non-pregnant patients were treated. Miconazole nitrate was administered once daily, at bedtime, for 14 days to 55 pregnant and non-pregnant patients. Overall, 74.5% (41 of 55 patients) were cured with one course of therapy. In contrast, of 40 nystatin-treated patients (both pregnant and non-pregnant) treated twice daily for 15 days, 22 patients (57.8%) were cured with one course of therapy. This difference in cure rates was statistically significant. Side effects were minimal and comparable in the two treatment groups. No recorded instances of birth defects were observed in infants born to mothers in either treatment group. Monistate Cream, in this study, was found to be a safe and effective drug in treating both pregnant and nonpregnant patients with confirmed candidiasis.
D000293:Adolescent; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008825:Miconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009761:Nystatin / Q000627:therapeutic use; D009824:Ointments; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D012075:Remission, Spontaneous; D013488:Suppositories
D007093:Imidazoles; D009824:Ointments; D013488:Suppositories; D009761:Nystatin; D008825:Miconazole